US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
ML

MLTXStock

Nasdaq Capital Market · Healthcare · CH

$10.68 last close 2026-10-12
Open in terminalCompare
Alert

Verdicts genuinely change. Free email alert the moment MLTX's does — no target price to set, unlike "Alert" above.

Sharia status
NOT COMPLIANT
Per In-house ratio engine
0 of 4 pass our own screen — 3 of 7 could not be computed
Purification 100.00% *
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
No trade setup shown — a stock that isn't cleanly Sharia-compliant never gets a bullish verdict here.

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure0 of 5 timeframes bullish · 39.1% aligned
VWAPPrice below VWAP ($10.74)
VolumeRelative volume 5.1× the 20-day average
Momentum10-day rate of change -6.3%

MLTX is currently considered not halal (non-compliant), per In-house ratio engine. See the full ratio breakdown and business-activity screen below for the reasoning.

⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.

449 other Healthcare stocks pass this same screen. See compliant Healthcare stocks →

Market & analysts
Price target
$28.54
+167.2% · 13 analysts
Institutional own.
87.8%
of shares
Momentum (10d)
-6.3%
rate of change
SMC grade
D · 36
39.1% aligned
100.00% *
Purification ratio (secondary provider, uncertain)
D · 36
SMC grade — 39.1% timeframe alignment
-6.3%
Rate of change (10d)
$28.54
Price target (+167.2%) · 13 analysts
87.8%
Institutional ownership

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2026-06-30. MLTX files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.

Business activity: cleared (no excluded categories detected)

AAOIFI Fail

RatioValueThresholdResult
Interest-bearing debt 7.99% 30.00% Pass
Interest-bearing investments 37.59% 30.00% Fail

Usmani Fail

RatioValueThresholdResult
Interest-bearing debt 17.69% 33.00% Pass
Interest-bearing investments 83.27% 33.00% Fail
Non-liquid assets 16.73% at least 20.00% Fail

MSCI Fail

RatioValueThresholdResult
Interest-bearing debt 17.69% 33.33% Pass
Cash + interest-bearing securities 83.27% 33.33% Fail
Accounts receivable 83.27% 33.33% Fail

FTSE Fail

RatioValueThresholdResult
Interest-bearing debt 17.34% 33.33% Pass
Cash + interest-bearing securities 83.27% 33.33% Fail
Accounts receivable 83.27% 50.00% Fail

Dow Jones Islamic Market Unverified⚠️ a figure this standard divides by was not available — the ratios shown were computed, this standard needs one more that was not

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 3.08% 33.00% Pass
Cash + interest-bearing securities 14.50% 33.00% Pass
Accounts receivable 0.00% 33.00% Pass

S&P Shariah Unverified⚠️ a figure this standard divides by was not available — the ratios shown were computed, this standard needs one more that was not

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 2.75% 33.00% Pass
Cash + interest-bearing securities 12.96% 49.00% Pass
Accounts receivable 0.00% 49.00% Pass

MSCI M-Series Unverified⚠️ a figure this standard divides by was not available — the ratios shown were computed, this standard needs one more that was not

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 2.75% 33.33% Pass
Cash + interest-bearing securities 12.96% 33.33% Pass
Accounts receivable 12.96% 49.00% Pass

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

How close is it to flipping?

Every current reading against its own line, closest first. A verdict is only as durable as that distance.

Usmani (% of total assets)debt ratio 15.3pts
MSCI Islamic Index (% of total assets)debt ratio 15.6pts
FTSE Shariah Global Equity Index Series (% of total assets)debt ratio 16.0pts
Usmani (% of total assets)investments ratio 50.3pts
MSCI Islamic Index (% of total assets)cash and interest ratio 49.9pts
MSCI Islamic Index (% of total assets)receivables ratio 49.9pts

The numbers the ratios are built from

Read from MLTX's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period not measured — —
Interest-bearing debtShort and long-term borrowings $99.5M 2026-06-30 LongTermDebt
Cash and interest-bearing securitiesCash, equivalents and marketable securities $477.9M 2026-06-30 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
Total assetsBalance sheet total $573.9M 2026-06-30 Assets
Market capDenominator for AAOIFI $1.3B live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series $2.8B 756 trading days closes x shares
24-month average market capDenominator for Dow Jones Islamic Market $2.4B 504 trading days closes x shares
Non-permissible revenueInterest and excluded income $27.7K 2021-12-31 InvestmentIncomeInterest

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

What changed, and when

Verdict history for MLTX. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-09-07 Compliant → Non Compliant watchlist re-scan

Tracked since 2026-09-07.

22.1618.9015.6412.389.122025-10-132026-04-142026-10-12

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
9.76
S2
10.08
S1
10.45
PIVOT
10.77
R1
11.14
R2
11.46
R3
11.83

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
13.54 – 16.58
±10.07% from 15.06, made 2026-09-02 · resolves 2026-09-09
STRONG SELL
from 19 indicators
61.9% of our last 5789 forecasts landed inside their stated range, and 49.9% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

STRONG SELL
19 indicators
OscillatorsSTRONG BUY
5 buy · 0 neutral · 2 sell
Moving averagesSTRONG SELL
0 buy · 0 neutral · 12 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)27.10BUY
Stochastic %K (14)18.43BUY
CCI (20)-106.33BUY
Williams %R (14)-81.57BUY
MACD (12,26,9)0.03BUY
ROC (10)-7.61SELL
Momentum (10)-0.88SELL
EMA (10)11.15SELL
SMA (10)11.12SELL
EMA (20)11.86SELL
SMA (20)11.76SELL
EMA (30)12.57SELL
SMA (30)12.59SELL
EMA (50)13.76SELL
SMA (50)14.18SELL
EMA (100)15.20SELL
SMA (100)16.63SELL
EMA (200)15.25SELL
SMA (200)16.68SELL

About MLTX

Healthcare · Biotechnology

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

moonlaketx.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Grade verdict

Weak — low conviction, small size or skip

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily RANGING 64
⏰ 4H BEARISH 36
🕐 1H RANGING 98
⏱ 15-Min BEARISH 130
⏲ 5-Min BEARISH 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

-6.3%
Rate of change (10d)
5.1×
Volume vs its 20-day average
-1.02
MACD (no fresh cross)
$10.91
Volume POC (today)
$10.75 – $10.93
Value area

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Still fetching insider filings — it ran past this page's budget, so the page painted without waiting. The fetch is still running; reload in a moment and it will be here.

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-10-06 · Asset managers net 906615 (+2612)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.

Tell us what's working, what's confusing, or what you want to see next — read by a real person, not a form that goes nowhere.